Rapid Improvement Following Receipt of Infliximab in Steroid-refractory Durvalumab-Associated Grade 3 Pneumonitis

Immune checkpoint inhibitors (ICIs) are important novel agents used in advanced non-small cell lung cancer (NSCLC) standard regimens; however, their use increases the risk of immune-related adverse effects (IRAEs). The incidence of IRAE pneumonitis is well documented in ICI use. Corticosteroids cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Sherri, Jordan, Aryanna, Jenneman, Dakota, Shafique, Michael, Holmstrom, Bjorn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933124/
https://www.ncbi.nlm.nih.gov/pubmed/35350507
http://dx.doi.org/10.7759/cureus.22295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933124/
https://www.ncbi.nlm.nih.gov/pubmed/35350507
http://dx.doi.org/10.7759/cureus.22295

Ejemplares similares